Clinical trial

Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

NCT03698994

Study summary

ClinicalTrials.gov

Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

Design: INTERVENTIONAL · Status: ACTIVE NOT RECRUITING · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

OTHER · Unmapped registry intervention Pharmacokinetic Study Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Ulixertinib Find medicine records · Find other trials using this name

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2018-11-14

PhasePHASE2

Conditions

Advanced Malignant Solid Neoplasmunresolved

Recurrent Ependymal Tumorunresolved

Recurrent Ewing Sarcomaunresolved

Recurrent Gliomaunresolved

Recurrent Hepatoblastomaunresolved

Recurrent Histiocytic and Dendritic Cell Neoplasmunresolved

Recurrent Langerhans Cell Histiocytosisunresolved

Recurrent Malignant Germ Cell Tumorunresolved

Recurrent Malignant Solid Neoplasmunresolved

Recurrent Medulloblastomaunresolved

Recurrent Neuroblastomaunresolved

Recurrent Non-Hodgkin Lymphomaunresolved

Recurrent Osteosarcomaunresolved

Recurrent Peripheral Primitive Neuroectodermal Tumorunresolved

Recurrent Primary Malignant Central Nervous System Neoplasmunresolved

Recurrent Rhabdoid Tumorunresolved

Recurrent Rhabdomyosarcomaunresolved

Recurrent Soft Tissue Sarcomaunresolved

Refractory Ependymomaunresolved

Refractory Ewing Sarcomaunresolved

Refractory Gliomaunresolved

Refractory Hepatoblastomaunresolved

Refractory Histiocytic and Dendritic Cell Neoplasmunresolved

Refractory Langerhans Cell Histiocytosisunresolved

Refractory Malignant Germ Cell Tumorunresolved

Refractory Malignant Solid Neoplasmunresolved

Refractory Medulloblastomaunresolved

Refractory Neuroblastomaunresolved

Refractory Non-Hodgkin Lymphomaunresolved

Refractory Osteosarcomaunresolved

Refractory Peripheral Primitive Neuroectodermal Tumorunresolved

Refractory Primary Malignant Central Nervous System Neoplasmunresolved

Refractory Rhabdoid Tumorunresolved

Refractory Rhabdomyosarcomaunresolved

Refractory Soft Tissue Sarcomaunresolved

Wilms Tumorverified · MONDO: Wilms tumor

Interventions

Pharmacokinetic StudyOTHER

UlixertinibDRUG

Sponsors & collaborators

National Cancer Institute (NCI)lead sponsor

Mapped research locations

New YorkNew York, United States4 St LouisMissouri, United States3 OrlandoFlorida, United States3 HoustonTexas, United States2 BostonMassachusetts, United States2 Los AngelesCalifornia, United States2 DallasTexas, United States2 BaltimoreMaryland, United States2 MiamiFlorida, United States2 San AntonioTexas, United States2 PortlandOregon, United States2 IndianapolisIndiana, United States2

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03698994 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.